The risk of cancer development in systemic sclerosis: A meta-analysis

Cancer Epidemiology

Volumn 37, Issue 5, 2013, Pages 523-527

  Zhang, Jun qing ^a,b   Wan, Ya nan ^a   Peng, Wen jia ^a   Yan, Jun wei ^a   Li, Bao zhu ^a   Mei, Bin ^a   Chen, Bing ^a   Yao, Hua ^a   Yang, Guo jun ^c   Tao, Jin hui ^c   Wang, Jing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Hefei City   (China)

^c ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Cancer; Meta analysis; Standardized incidence rate; Systemic sclerosis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; DISEASE ASSOCIATION; HUMAN; LUNG CANCER; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

CANCER; META-ANALYSIS; STANDARDIZED INCIDENCE RATE; SYSTEMIC SCLEROSIS;

CHINA; FEMALE; HUMANS; MALE; NEOPLASMS; SCLERODERMA, SYSTEMIC;

EID: 84884160618     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.04.014     Document Type: Article

References (25)

1. Gilliam A.C. Scleroderma. Curr Dir Autoimmun 2008, 10:258-279.
2. Leroy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
3. Coral-Alvarado P., Pardo A.L., Castaño-Rodriguez N., Rojas-Villarraga A., Anaya J.M. Systemic sclerosis: a world wide global analysis. Clin Rheumatol 2009, 28:757-765.
4. Barnes J., Mayes M.D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012, 24:165-170.
5. Derk C.T., Rasheed M., Artlett C.M., Jimenez S.A. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006, 33(6):1113-1116.
6. Olesen A.B., Svaerke C., Farkas D.K., Sørensen H.T. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010, 163(4):800-806.
7. Chatterjee S., Dombi G.W., Severson R.K., Mayes M.D. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005, 52(8):2415-2424.
8. Hill C.L., Nguyen A.M., Roder D., Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62(8):728-731.
9. Kuo C.F., Luo S.F., Yu K.H., Chou I.J., Tseng W.Y., Chang H.C., et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012, 41(1):44-49.
10. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008, 101(1):59-62.
11. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
13. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
14. Rosenthal A.K., McLaughlin J.K., Gridley G., Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995, 76(5):910-914.
15. Hashimoto A., Arinuma Y., Nagai T., Tanaka S., Matsui T., Tohma S., et al. Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med 2012, 51:1683-1688.
16. Rosenthal A.K., McLaughlin J.K., Linet M.S., Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993, 52(7):531-533.
17. Nietert P.J., Sutherland S.E., Silver R.M., Pandey J.P., Knapp R.G., Hoel D.G., et al. Is occupational organic solvent exposure a risk factor for scleroderma?. Arthritis Rheum 1998, 41(6):1111-1118.
18. Chaudhary P., Chen X., Assassi S., Gorlova O., Draeger H., Harper B.E., et al. Cigarette smoking is not a risk factor for systemic sclerosis. Arthritis Rheum 2011, 63:3098-3102.
19. Pontifex E.K., Hill C.L., Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007, 66(4):551-553.
20. Abu-Shakar M., Guillemin F., Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993, 36:460-464.
21. Pan S.F., Rodnan G.P., Deutsch M., Wald N. Chromosomal abnormalities in progressive systemic sclerosis (scleroderma) with consideration of radiation effects. J Lab Clin Med 1975, 86:300-308.
22. Leone G., Pagano L., Ben-Yehuda D., Voso M.T. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007, 92:1389-1398.
23. Kishi S., Yang W., Boureau B., Morand S., Das S., Chen P., et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004, 103:67-72.
24. Marasini B., Conciato L., Belloli L., Massarotti M. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009, 22:573-578.
25. Shah A.A., Rosen A. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol 2011, 23(6):530-535.